Veracyte VCYT 深 沪
等待开盘 07-07 09:30:00 美东时间
57.995
+0.915
+1.60%
华盛通- 最 高59.96
- 今 开56.04
- 成交量 89.46万股
- 最 低 56.01
- 昨 收 57.08
- 总市值 46.28亿
- 52周最高 60.91
- 市盈率 静 70.43
- 换手率 1.12%
- 52周最低 22.61
- 委 比 -64.80%
- 总股本 7979.26万
- 历史最高 86.03
- 量 比 0.52
- 振 幅 6.92%
- 历史最低 4.21
- 每 手 1
- 风险率 7.70%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 康托·菲茨杰拉德大幅上调AMD、英特尔、迈威尔科技、美光、西部数据目标价！Applied、INIO、LFTO、Quantinuum获多家大行首予买入评级
今日重点评级关注：Evercore ISI集团：维持ProQR Therapeutics"跑赢大市"评级，目标价从5美元升至6美元；摩根士丹利：维持霍尼韦尔"标配"评级，目标价从245美元升至490美元
06-30 10:14
Guggenheim Maintains Buy on Veracyte, Raises Price Target to $65
Guggenheim analyst Subbu Nambi maintains Veracyte (NASDAQ:VCYT) with a Buy and raises the price target from $45 to $65.
06-29 22:06
美股大行评级 | 瑞杰金融上调美光目标价从530美元升至1100美元；AMD、Arm、戴尔、英特尔等获多家机构上调目标价
今日重点评级关注：Ascendiant Capital：维持RenovoRx"买入"评级，目标价从13.5美元升至14美元；BTIG：维持Jade Biosciences"买入"评级，目标价从39美元升至74美元
06-02 16:25
Veracyte Commercially Rolls Out Prosigna Breast Risk Of Recurrence Test Across U.S.
On the heels of the landmark OPTIMA trial readout presented at the ASCO Annual Meeting, Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced the U.S. commercial launch of the
06-01 19:33
Veracyte To Present Results From Independent OPTIMA Trial, Led By University College London, At ASCO Annual Meeting
Highest level of prospective evidence supports test-directed chemotherapy decisions in broadest high-risk population to-date, including premenopausal women and patients with extensive lymph node involvementStudy shows
05-30 03:17
美股大行评级 | 瑞穗上调戴尔目标价至350美元！华尔街齐上调迈威尔科技目标价；瑞银大幅上调Snowflake目标价
瑞穗上调戴尔目标价至350美元！华尔街齐上调迈威尔科技目标价；瑞银大幅上调Snowflake目标价
05-29 18:09
Needham Reiterates Buy on Veracyte, Maintains $48 Price Target
Needham analyst Mike Matson reiterates Veracyte (NASDAQ:VCYT) with a Buy and maintains $48 price target.
05-28 18:29
美股大行评级 | 绩后暴跌10%，ARM仍获高盛、富国银行等多家大行上调目标价；康宁、优步、飞塔信息、西维斯、Agilon Health等获多家大行上调目标价
今日重点评级关注：Citizens：维持BioCryst制药"跑赢大市"评级，目标价从25美元升至28美元；富国银行：维持曼恩凯德生物医疗"超配"评级，目标价从8美元升至10美元
05-08 12:05
美股大行评级 | 潜在涨幅20%！15家机构集体上调AMD目标价；Lumentum、神经分泌生物科学、伊顿公司、美国电力等获多家大行上调目标价
今日重点评级关注：Citizens：维持Avalo Therapeutics"跑赢大市"评级，目标价从52美元升至62美元；BTIG：维持Avalo Therapeutics"买入"评级，目标价从40美元升至58美元
05-07 12:37
UBS Maintains Buy on Veracyte, Raises Price Target to $52
UBS analyst Lu Li maintains Veracyte (NASDAQ:VCYT) with a Buy and raises the price target from $48 to $52.
05-07 06:28
